skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treatment of cutaneous melanoma: current approaches and future prospects

Review

(2887) Views  (1040) Full article downloads

Authors: Alain P Algazi, Christopher W Soon, Adil I Daud

Published Date August 2010 Volume 2010:2 Pages 197 - 211
DOI: http://dx.doi.org/10.2147/CMAR.S6073

Alain P Algazi1, Christopher W Soon2, Adil I Daud1

1Department of Medicine, Division of Hematology and Oncology, 2Department of Dermatology, University of California, San Francisco San Francisco, CA, USA

Abstract: Melanoma is the most aggressive and deadly type of skin cancer. Surgical resection with or without lymph node sampling is the standard of care for primary cutaneous melanoma. Adjuvant therapy decisions may be informed by careful consideration of prognostic factors. High-dose adjuvant interferon alpha-2b increases disease-free survival and may modestly improve overall survival. Less toxic alternatives for adjuvant therapy are currently under study. External beam radiation therapy is an option for nodal beds where the risk of local recurrence is very high. In-transit melanoma metastases may be treated locally with surgery, immunotherapy, radiation, or heated limb perfusion. For metastatic melanoma, the options include chemotherapy or immunotherapy; targeted anti-BRAF and anti-KIT therapy is under active investigation. Standard chemotherapy yields objective tumor responses in approximately 10%–20% of patients, and sustained remissions are uncommon. Immunotherapy with high-dose interleukin-2 yields objective tumor responses in a minority of patients; however, some of these responses may be durable. Identification of activating mutations of BRAF, NRAS, c-KIT, and GNAQ in distinct clinical subtypes of melanoma suggest that these are molecularly distinct. Emerging data from clinical trials suggest that substantial improvements in the standard of care for melanoma may be possible.

Keywords: melanoma, resection, immune modulation, small molecule kinase inhibitors, chemotherapy, clinical trials







Readers of this article also read:

Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer
Role of bevacizumab therapy in the management of glioblastoma
Management of metastatic renal cell carcinoma in patients with poor prognosis
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials
Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients
HER2-positive male breast cancer: an update
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection
Targeted agents for the treatment of metastatic melanoma
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University